Lampl C, et al. - A potential refractory chronic cluster headache (CCH) patient group was provided treatment with onabotulinumtoxinA (BoNT-A; Botox, 150 Allergan IU) to assess its efficacy in these patients. Researchers achieved encouraging results after treatment with BoNT-A in this study population. Seventeen male patients (aged 32 ± 11 [mean ± SD] years) with a mean disease length of 6.6 years received the treatment; of these, 58.8% showed > 50% reduction in headache minutes, and 29.4% experienced an improvement of 30–50%. They also noted a significant reduction in frequency of headache days and intensity of remaining attacks. A trend to improvement was observed in headache disability scores after BoNT-A.